Development of a Nonpsychotropic Cannabinoid Agonist for the Treatment of Sclerod
JB THERAPEUTICS, INC. · Department of Health and Human Services
Phase I2012$294,381
DESCRIPTION (provided by applicant): Systemic sclerosis (SSc; scleroderma) is a complex multisystem autoimmune disease of unknown cause associated with early transient inflammation and vascular injury followed by progre…